Journal of Dali University ›› 2024, Vol. 9 ›› Issue (8): 46-52.DOI: 10. 3969 / j. issn. 2096-2266. 2024. 08. 008
Previous Articles Next Articles
Rong Nana1, Zhu Jialiang2, Liu Jihua1, Wang Ying1, Wu Jing1*
Received:
Revised:
Online:
Published:
Abstract: Objective: To establish a method for the determination of related substances in hydrocortisone butyrate cream. Methods: Kromasil XDB-C18( 4.6 mm×250 mm, 5 μm) column was used for gradient elution with acetonitrile-0.5% glacial acetic acid solution as the mobile phase. Detection was performed at a wavelength of 254 nm, and methodological validation was performed on the established method. Results: Hydrocortisone butyrate was well separated from all impurities and had good linear relationship in the range of 0.05~ 7.50 μg/mL. In all samples, hydrocortisone 21-butyrate was the highest single impurity, and the contents of hydrocortisone and other unknown impurities were less than 0.26%, and the total impurities ranged from 0.37% to 2.72%. Under the condition of oxidation, high temperature and strong light, hydrocortisone butyrate cream had good stability, and the impurity content did not increase significantly. Under the condition of strong acid and strong base, hydrocortisone butyrate was easily degraded to produce hydrocortisone 21-butyrate. Conclusion: The method established in this study has the advantages of good specificity, high sensitivity and low cost, which can provide an important reference for the quality control of hydrocortisone butyrate cream.
Key words: hydrocortisone butyrate cream, hydrocortisone, hydrocortisone 21-butyrate, quality control, destructive test
CLC Number:
R917
Rong Nana, Zhu Jialiang, Liu Jihua, Wang Ying, Wu Jing. Determination of Related Substances in Hydrocortisone Butyrate Cream by HPLC[J]. Journal of Dali University, 2024, 9(8): 46-52.
0 / / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: http://journal15.magtechjournal.com/Jwk_dlxyzk/EN/10. 3969 / j. issn. 2096-2266. 2024. 08. 008
http://journal15.magtechjournal.com/Jwk_dlxyzk/EN/Y2024/V9/I8/46
用〔J〕. 继续医学教育,2006,20(33):59-60.
〔4〕 蒋芳. 168例湿疹皮炎类皮肤病患者丁酸氢化可的松乳 膏治疗体会〔J〕. 中国卫生产业,2011,8(23):77. 〔5〕 付志媛,丁志军. 丁酸氢化可的松乳膏原辅料相容性研 究〔J〕. 药品评价,2021,18(6):331-333. 〔6〕 孙亮,陈松,赵琳. 一种丁酸氢化可的松乳膏: CN200910228788. 0〔P〕. 2010-08-25. 〔7〕 国家药典委员会. 中华人民共和国药典:四部〔M〕. 北 京:中国医药科技出版社,2020:483-485. 〔8〕 国家药品监督管理局. 化学药物杂质研究的技术指导原 则〔EB/OL〕. (2005-03-11)〔2023-03-18〕. https://www. nmpa. gov. cn/wwwroot/gsz05106/03. pdf. 〔9〕 国家药品监督管理局药审中心. 皮肤外用化学仿制药研 究技术指导原则(试行)〔EB/OL〕.( 2021-03-03)〔2023- 03-18〕. https://lcylky. nyfy. com. cn/info/1052/1334. htm. 〔10〕 刘智豪,衡伟利,钱帅,等. 皮肤外用制剂的流变学研究 进展〔J〕. 中国药科大学学报,2022,53(1):105-112. 〔11〕 宫克,郭建辉,杜凯晴,等. 复方紫连膏联合丁酸氢化可 的松乳膏治疗脾虚湿蕴证亚急性婴幼儿湿疹的临床效 果〔J〕. 中国医药导报,2022,19(21):107-110. 〔12〕 王毅红,孙晓峰,赵红纪. 维生素D缺乏与儿童湿疹严 重程度及丁酸氢化可的松治疗效果分析〔J〕. 中国中西 医结合皮肤性病学杂志,2021,20(2):189-191. 〔13〕 孙卓. 丁酸氢化可的松联合复方炉甘石洗剂治疗新生 儿湿疹的效果研究〔J〕. 中国医药指南,2021,19(1): 63-64. 〔14〕 黑扎提·阿力哈孜,茹孜古丽·伊明江. 观察丁酸氢化可 的松辅治新生儿湿疹的临床效果〔J〕. 世界最新医学信 息文摘(连续型电子期刊),2019,19(22):130. (责任编辑 李 杨) Determination of